Streetbeat News

Regulatory

BLUE

Bluebird Bio expects 85 to 105 patient starts across its three commercial products in 2024, following FDA approval of Lyfgenia. The company has also signed an outcomes-based agreement with an organization covering approximately 100 million U.S. persons.

Portfolio Pulse from Charles Gross

December 14, 2023 | 12:38 pm

AAPL

GOOG

GOOGL

Apple Inc. has launched a new web-based diagnostic tool that allows customers to remotely check and repair their iPhones and MacBooks. The tool supports iPhone 12 and later, including the iPhone 15 series, as well as M2-powered MacBooks, Mac Mini, Mac Pro, and Mac Studio. This initiative follows Apple's support for the Right to Repair bill, enabling both customers and third-party service providers to access repair tools. Apple's self-service repair tools are now available in 33 countries and 35 products. Alphabet Inc.'s Google also supports the Right to Repair movement with seven years of software updates for its Pixel 8 series.

Portfolio Pulse from Rounak Jain

December 14, 2023 | 12:27 pm

TECH

Bio-Techne's subsidiary Lunaphore and the SIB Swiss Institute of Bioinformatics have received Innosuisse funding to develop AI-based assay development tools for spatial biology on Lunaphore's COMET platform. This initiative aims to accelerate the adoption of multiplex sequential immunofluorescence, a technique used in spatial biology.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 12:22 pm

NVDA

TSM

Nvidia Corp has placed orders for AI processors designed for the Chinese market with Taiwan Semiconductor Manufacturing Company, with production starting in Q1 2024. Due to U.S. restrictions, Nvidia faces challenges in selling its advanced AI chips in China, and plans to release new GPUs that comply with performance limits. Chinese chip designers are emerging as competitors in the AI chip market, where Nvidia holds a 90% share. NVDA shares were up 0.91% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

December 14, 2023 | 12:17 pm

APLS

Apellis Pharmaceuticals was informed of a negative trend vote regarding its European application for Pegcetacoplan. The company anticipates a negative opinion from the CHMP at its January meeting and plans to appeal and seek re-examination if this occurs.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 12:14 pm

AAPL

AMZN

Amazon.com Inc (NASDAQ:AMZN) won a legal battle in the EU's top court, negating a €250 million tax bill from the European Commission. The court ruled that Amazon's tax deal with Luxembourg wasn't illegal state aid. This is a blow to EU Competition Chief Margrethe Vestager's efforts against tax advantages for large firms. The ruling may influence similar cases, like Apple Inc's (NASDAQ:AAPL) pending €13 billion tax order. Amazon's stock saw a slight increase in premarket trading.

Portfolio Pulse from Anusuya Lahiri

December 14, 2023 | 12:14 pm

USO

The International Energy Agency (IEA) forecasts a slowdown in oil demand through 2024, contrasting with OPEC+'s more optimistic outlook. The IEA cites a 'decidedly bearish' market sentiment and predicts a reduction in oil consumption growth next year due to weaker global economic performance and diminishing Covid-19 impacts. This comes as the COP28 climate summit pushes for a transition from fossil fuels. The United States Oil Fund (USO) saw a pre-market drop of 0.2% following a 3.8% loss, reflecting the pressure on oil prices.

Portfolio Pulse from Benzinga Neuro

December 14, 2023 | 12:12 pm

TLSI

TriSalus Life Sciences has announced that the Centers for Medicare & Medicaid Services (CMS) will reimburse the TriNav Infusion System, which has been assigned a new Technology Healthcare Common Procedure Coding System (HCPCS) code. This development is significant for the company as it facilitates the adoption of the TriNav Infusion System by healthcare providers by ensuring they can be reimbursed for its use.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 12:10 pm

GKOS

The FDA has approved Glaukos Corporation's iDose TR, a travoprost intracameral implant designed to reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma. This approval allows for a single administration per eye of the 75 mcg dosage.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 12:05 pm

CNRCF

Canter Resources Corp. (OTC:CNRCF) has received approval for water permits from the Nevada Division of Water Rights, allowing the appropriation of 2,235.64 acre-feet of groundwater annually for its Columbus Lithium-Boron Project in Nevada. This development is crucial for the project's advancement, especially given the region's water access challenges. Lithium is a key component in EV batteries, and the demand for it is growing with the rise of sustainable transportation. Canter Resources plans to begin Phase 1 drilling in the first quarter of 2024.

Portfolio Pulse from Melanie Schaffer

December 14, 2023 | 12:00 pm